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Integrative computational approach identifies drug targets in
CD4+ T-cell-mediated immune disorders
Bhanwar Lal Puniya 1, Rada Amin1, Bailee Lichter1,5, Robert Moore1,5, Alex Ciurej1, Sydney J. Bennett1, Ab Rauf Shah1,
Matteo Barberis 2,3,4✉ and Tomáš Helikar 1✉
CD4+ T cells provide adaptive immunity against pathogens and abnormal cells, and they are also associated with various immune-
related diseases. CD4+ T cells’ metabolism is dysregulated in these pathologies and represents an opportunity for drug discovery
and development. Genome-scale metabolic modeling offers an opportunity to accelerate drug discovery by providing high-quality
information about possible target space in the context of a modeled disease. Here, we develop genome-scale models of naïve, Th1,
Th2, and Th17 CD4+ T-cell subtypes to map metabolic perturbations in rheumatoid arthritis, multiple sclerosis, and primary biliary
cholangitis. We subjected these models to in silico simulations for drug response analysis of existing FDA-approved drugs and
compounds. Integration of disease-specific differentially expressed genes with altered reactions in response to metabolic
perturbations identified 68 drug targets for the three autoimmune diseases. In vitro experimental validation, together with
literature-based evidence, showed that modulation of fifty percent of identified drug targets suppressed CD4+ T cells, further
increasing their potential impact as therapeutic interventions. Our approach can be generalized in the context of other diseases,
and the metabolic models can be further used to dissect CD4+ T-cell metabolism.
npj Systems Biology and Applications             (2021) 7:4 ; https://doi.org/10.1038/s41540-020-00165-3
INTRODUCTION
CD4+ T cells are essential components of the human immune
system that fight against pathogenic invaders and abnormal cells
by producing cytokines and stimulating other cells, such as B cells,
macrophages, and neutrophils1. During an immune response,
CD4+ T cells are activated and proliferate, and their metabolism
adjusts to fulfill increased bioenergetic and biosynthetic demands.
For example, activated effector CD4+ T cells are highly glycolytic2
and use aerobic glycolysis and oxidative phosphorylation
(OXPHOS) for proliferation3. On the other hand, naïve, resting,
and regulatory CD4+ T cells are less glycolytic and use OXPHOS
and fatty acid oxidation (FAO) for energy generation. Accordingly,
metabolically dysregulated CD4+ T cells were observed in several
diseases such as diabetes4, atherosclerosis5, cancers6, and auto-
immune diseases such as rheumatoid arthritis (RA)7,8, multiple
sclerosis (MS)9, primary biliary cholangitis (PBC)10, and systemic
lupus erythematosus (SLE)11,12. Furthermore, metabolism of Type
1 T helper (Th1), Type 17 T helper (Th17), and inducible regulatory
T cells have been found to be dysregulated in MS13. Controlling
CD4+ metabolic pathways can be important in fighting against
some immune diseases. For example, CD4+ T cells are hyperactive
in systemic lupus erythematosus (SLE), and inhibiting glycolysis as
well as the mitochondrial metabolism improved the outcome in
an animal model14. Together, this evidence suggests a significant
role of CD4+ T-cell metabolism in immune-mediated diseases.
Repurposing existing drugs for novel indications represents a
cost-effective approach for the development of new treatment
options15. Several studies have recently demonstrated the
potential for drug repurposing in CD4+ T-cell-mediated dis-
eases16,17. For example, 2-deoxy-D-glucose (anticancer agent) and
metformin (antidiabetic drug) were shown to reverse SLE in a
mouse model14. However, drug repurposing, as well as drug
discovery and development efforts for targeting T-cell metabo-
lism, have been limited due to the lack of knowledge about the
key molecular targets in this context.
In recent years, analysis of large-scale biological datasets has
emerged as a powerful strategy for discovering novel mechan-
isms, drug targets, and biomarkers in human diseases18–21. Here,
we develop a computational modeling approach that integrates
multi-omic data with systematic perturbation analyses of newly
constructed whole-genome metabolic models of naïve CD4+
T cells and Th1, Th2, and Th17 cells. This led to identifying
potential drug targets for CD4+ T-cell-mediated diseases (RA, MS,
and PBC).
RESULTS
Identification of genes expressed in the CD4+ T cells
We used the computational approach shown in Fig. 1 (see also
Supplementary Methods 1) to construct metabolic models of
naïve and effector CD4+ T cells. To identify metabolic genes
expressed across CD4+ T-cell subtypes (naïve, Th1, Th2, and Th17
cells), we integrated transcriptomics22–30 and proteomics data31
(see Materials and methods; Supplementary Data 1). The
comparison of genes expressed in CD4+ T-cell subtypes identified
by different datasets is shown in Supplementary Fig. 1. The
analysis showed that between 675 and 836 metabolic genes were
expressed depending on the CD4+ T-cell subtype (Supplementary
Data 2). Of these, 530 genes were expressed in all subtypes (Fig.
2a). On the other hand, 16, 25, 7, and 96 genes were specific to
naïve, Th1, Th2, and Th17 cells, respectively. Pathway enrichment
analysis using expressed metabolic genes suggested 6 enriched
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KEGG pathways common across all subtypes: carbon metabolism,
TCA cycle, oxidative phosphorylation (OXPHOS), amino sugar and
nucleotide sugar metabolism, and valine, leucine, and isoleucine
degradation (Fig. 2b). Fatty acid degradation and pentose
phosphate pathway were enriched in naïve CD4+ T cells only,
and fatty acid metabolism was enriched in the naïve, Th2, and
Th17 subtypes. No specific KEGG pathways were found enriched
solely in Th1 and Th17 cells. Among the enriched pathways shared
by all CD4+ T cells, the TCA cycle was enriched more than two-fold
in naïve, Th1, and Th2 subtypes. Similarly, OXPHOS was enriched
more than two-fold in naïve and Th1 subtypes (Fig. 2c). These
results suggest that key metabolic pathways are active across all
the subtypes. Importantly, the metabolism of various CD4+ T-cell
subtypes can be different with respect to these pathways’ levels of
activity and the number of reactions active within the pathways.
Development and validation of genome-scale metabolic
models of CD4+ T cells
To further examine these issues, we developed constraint-based
metabolic models specific to naïve CD4+ T cells, Th1, Th2, and
Th17 cells. Genome-scale constraint-based metabolic models
include a structural representation of a cell’s entire biochemical
reactions and help in computing biochemically feasible functional
states32. These models consist of a stoichiometry matrix of
biochemical reactions, exchange reactions (connecting cells
internal metabolism with the environment), and additional
constraints for upper and lower bounds for fluxes to be identified.
Using modeling approaches such as Flux Balance Analysis, these
models can be solved to predict flux distribution. In addition to
identifying feasible flux distribution, the constraint-based models
are useful in understanding human disease and identifying drug
targets, modeling interspecies interactions, and metabolic analysis
of across strains and species33. Our genome-scale metabolic
models consist of 3956 to 5282 reactions associated with 1055 to
1250 genes (Supplementary Table 1; Supplementary Data 3–6).
The number of internal enzyme-catalyzed reactions was 2501,
1969, 2549, and 2640 for naïve, Th1, Th2, and Th17 models,
respectively, distributed across 84 metabolic pathways (Supple-
mentary Fig. 2; note that transport and exchange reactions were
excluded). The models include more genes associations than
expressed genes identified from the data because the model-
building algorithm inserts some reactions that are not supported
by data but required for the model to achieve essential metabolic
functions for biomass production (see Materials and methods).
Furthermore, the algorithm kept the complete gene rules
associated with reactions catalyzed by multiple isozymes if one
of them was expressed in the data. Thus, the final models
comprise ~30% more genes than found in the data. Removing the
unexpressed genes would not delete the model’s reaction
because the data support at least one isozyme. We compared
our models with an existing model for naïve CD4+ T cell
(CD4T167034) (Supplementary Table 1). Since our models exclude
blocked reactions and dead ends, we have removed dead ends
from CD4T1670 for fair comparisons. Since we based all models of
this study on the more recent human metabolic network
Recon3D35, they include more reactions and metabolites than
CD4T1670, based on Recon236.
We validated the models based on the active pathways and
gene essentiality. We first identified pathways that are known to
be active in different CD4+ T-cell subtypes (see Materials and
methods) and searched for their activity (with non-zero fluxes) in
the corresponding models through Flux Balance Analysis (FBA).
Several major pathways were in agreement with the literature.
These include glycolysis, TCA cycle, glutaminolysis, and pyruvate
to lactate conversion (aerobic glycolysis) that showed non-zero
flux in all the models. We present an illustrative flux map of the
pathways mentioned above for the naïve model in Fig. 3. The
figure also indicates flux differences with the Th1 model for critical
reactions. Flux maps for the Th1, Th2, and Th17 models are shown
in Supplementary Figs. 3–5. Furthermore, we show some specific
Fig. 1 Integrative approach for the identification of potential metabolic drug targets. The computational approach comprised of five
major steps: (1) Construction of metabolic models using integrated transcriptomics and proteomics data, (2) Identification of metabolic genes
that are targets for existing drugs/compounds, (3) In silico inhibition of targets of existing drugs to identify affected reactions, (4) Identification
of differentially expressed genes (DEGs) in autoimmune diseases and their integration with flux ratios (Fluxperturbed /FluxWT), and (5) Validation
with literature and prediction of new targets.
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observed behaviors of CD4+ T cells collected from the literature
used for validation in Table 1. For comparison, we also performed
these validations in CD4T1670, also shown in Table 1. In all the
models developed in this study, limiting glucose from the
environment resulted in a decreased growth rate (Fig. 4a), which
is in agreement with existing knowledge37,38 but not reproduced
by the CD4T1670 model (Supplementary Fig. 6). All our models
produced lactate39 (Table 1, Supplementary Fig. 7). Literature
shows that increasing PDHm (pyruvate dehydrogenase) by
inhibiting PDHK (pyruvate dehydrogenase kinase) would redirect
flux from pyruvate to TCA cycle and, therefore, will decrease the
lactate production38. This was reproduced by our models (Fig. 4b).
Our models were also able to reproduce the essentiality of
Leucine, Arginine, and ACC1 for T-cell growth (Table 1), in
agreement with the literature38. It is important to note that the
activity of some pathways in the models was not agreeing or
partially agreeing with the literature. Specifically, we did not
observe a significant effect on growth rate when glutamine40 was
removed from exchange reactions in the effector CD4+ T-cell
models (Fig. 4c). However, literature has shown that while
transporters of glutamine in activated CD4+ T cells are dispen-
sable, removal of glutamine is critical and affects growth38. Our
systematic analyses showed that (1) inhibiting glutamine synthase
(GLNS) (that converts glutamate to glutamine) in the absence of
glutamine uptake in the model decreases growth to zero, and (2)
glutamine can have an impact on growth when glucose
availability is limited (less than 2mmol/g.DW/hr) (Fig. 4d). Using
CD4T1670, we observed no effect on biomass when varying
glutamine in the presence and absence of glucose (Supplemen-
tary Fig. 8). Thus, we may hypothesize that glutamine might be
conditionally critical for CD4+ T cells specifically when the
availability of other nutrients is low.
Next, we predicted essential genes and compared the results
against independent data to identify the overlap between genes
predicted by our models and identified from experiments.
Because large-scale essentiality datasets were not available for
CD4+ T cells, we used essentiality datasets available for different
human cancer cell lines. Gene deletion analysis predicted 84, 95,
81, and 84 genes as essential in the naïve, Th1, Th2, and Th17
models, respectively (Supplementary Data 7). More than 70% of
these predictions agreed with genes experimentally defined as
essential and conditionally essential in those different but related
cell lines41 (Supplementary Fig. 9). To assess if higher-ranked
predictions compared better with gene essentiality data, we
generated precision-recall curves using 84, 95, 81, and 84 genes,
respectively, from each model that were identified as essential.
The area under the curve for all models was >75% (Supplementary
Figs. 10–13). Additional validations based on CD4+ T-cell-specific
essential functions are presented in Supplementary Methods 3.
Overall, the validation confirmed that our constraint-based
metabolic models specific to naïve CD4+ T cells, Th1, Th2, and
Th17 cells represent relevant and realistic systems to examine
drug response and predict drug targets.
Mapping existing and identifying potential drug targets in
CD4+ T cells
We used the validated CD4+ T-cell-specific models to predict
potential drug targets and combined it with the publicly available
drug repurposing and tool compound data set from the
Connectivity Map (cMap) database and mapped the approved
drugs, clinical drug candidates, and tool compounds in the dataset
with the metabolic genes in the models (Fig. 5a). Next, we
performed in silico knock-outs of the associated drug target
genes. Due to the presence of isozymes, not all the deleted target
genes influenced the reaction(s). We identified 86, 79, 86, and 90
target genes whose deletion blocks at least one associated
reaction in naïve, Th1, Th2, and Th17 models, respectively (Fig. 5b).
In turn, these disruptions block multiple downstream reactions. Of
these, 62 were common among four CD4+ T-cell subtypes (Fig.
5c). Four genes were targeted only in Th1 cells. All modeled gene
deletions resulted in altered flux distributions that were quantified
using flux ratios. For each drug target deletion, we classified all
reactions into three categories (see Materials and methods): (1)
reactions with decreased fluxes (down-reactions), (2) reactions
with increased fluxes (up-reactions), and (3) reactions without any
changes. We used these flux ratios to identify potential drug
targets specific for immune diseases by exploring how disease-
specific metabolic functions are affected upon each drug target
inhibition.
First, we identified disease-specific metabolic functions for RA,
MS, and PBC using differential gene expression analysis of publicly
Fig. 2 Construction of metabolic models in CD4+ T cells. a Expressed metabolic genes identified using integrated transcriptomics and
proteomics data of CD4+ T-cell subtypes. b KEGG pathway enrichment analysis of expressed genes in each cell type using all 1892 metabolic
genes as a background. c Fold enrichment and P-values (larger sizes correspond to lower P-values) of KEGG pathways enriched across CD4+
T-cell subtypes. A pathway was considered significantly enriched with P-value < 0.05 and false discovery rate (FDR) <5%.
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available patients’ data (Case–Control studies) (see Materials and
methods). We identified 986, 472, and 545 differentially expressed
genes (DEGs) (Benjamini & Hochberg Padj < 0.05) for RA, MS, and
PBC, respectively (Supplementary Data 8). From these DEGs, we
selected genes relevant to our metabolic models. For example, 38
metabolic genes were upregulated and 29 genes were down-
regulated in RA (Fig. 5d). Biological process enrichment analysis
(Fisher’s exact FDR < 0.05) identified purine metabolism and starch
sucrose metabolism as enriched in upregulated genes. On the
contrary, lysine degradation, fatty acid elongation, and carbon
metabolism were downregulated. Enriched metabolic pathways
for all three diseases are shown in Supplementary Data 8.
To identify potential drug targets for the aforementioned
diseases, we looked for target genes whose deletion (inhibition)
would have the appropriate effect on diseases’ DEGs. For each
gene inhibition, we specifically investigated the decrease in
metabolic flux through reactions controlled by genes upregulated
in disease and increase in metabolic flux through reactions
controlled by genes downregulated in disease (Fig. 5e). Using flux
ratios of metabolic DEGs, we calculated a perturbation effect score
Fig. 3 Flux map of metabolic pathways active in CD4+ T-cell metabolic models. Escher map showing fluxes through glycolysis, glucose to
lactate conversion, TCA cycle, glutaminolysis in naïve model. The colors represent the reaction fluxes in the naïve model. Gray arrow color
corresponds to zero flux. Gradients of blue, green, and red correspond to non-zero flux. For key reactions, flux comparison between naïve and
Th1 is shown through bar plots. Both naïve and Th1 models convert pyruvate to lactate (aerobic glycolysis). In glycolysis, the naïve model had
the reverse direction flux through PGI reaction, while Th1 cells have forward direction flux. All the models exhibit an uptake of glutamine that
ultimately forms α-Ketoglutaric acid (glutaminolysis). GLNtm (glutamine transporter) and GLUNm (convert glutamine to glutamate) reactions
are active in the naïve model and not in models that use different routes for glutamine to glutamate conversion.
B.L. Puniya et al.
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(PES; see Materials and methods) for each drug target gene in
each pair model/disease. PES represents the effect of gene
inhibition on both upregulated and downregulated genes. A
positive PES value for the drug target gene means that its
inhibition decreases more fluxes controlled by genes upregulated
in disease than it increases, or increases more fluxes controlled by
genes downregulated in disease than it decreases. As such,
inhibition of that gene target reverses the fluxes controlled by
disease DEGs. In contrast, a negative PES means that the inhibition
of a target gene increases more fluxes controlled by upregulated
genes or decrease the more fluxes controlled by downregulated
genes than the opposite. Among the different combinations of
cell types and diseases, the PESs range was from −2 to 2
(Supplementary Fig. 14). Based on these considerations, genes
with higher positive PES can serve as potential drug targets for the
disease.
Using PES as a measure of target relevance, we identified 62
potential drug targets that were common to our models (Fig. 5c).
These genes displayed various PES ranks across models and
diseases. To choose drug targets that performed better across
different CD4+ T cells, we considered PES ranks of the four
subtype-specific models. First, we normalized the PES ranks by
transforming them into Z-scores in each model. Since the studied
autoimmune diseases typically involve more than one type of
CD4+ T-cell subtype, we next summed up the Z-scores of all the
models within a disease for each drug target (Supplementary Fig.
14). A minimum aggregate Z-score represents overall high PES
ranks predicted across four cell types. Therefore, a gene with a
minimum aggregated Z-score could be a potential high con-
fidence drug target. We used a Z-score cutoff of −1 (1 standard
deviation lower than the mean aggregated Z-score) and identified
17, 27, and 24 potential drug targets for RA, MS, and PBC,
respectively (Table 2; see more details in Supplementary Table 2).
Ranking based on aggregated Z-scores is provided in Supple-
mentary Data 9. Taken together, our combined use of the disease-
matched genome-scale metabolic models of CD4+ T cells and the
well target-annotated public dataset of bioactive compounds
generated a manageable list of potential drug targets suitable for
deeper analysis and follow-up.
Analysis and validation of predicted drug targets
To further analyze and validate our target list, we performed a
comprehensive literature survey (Table 2; see more details in
Supplementary Table 2). Among the 17 suggested drug targets for
RA, dihydroorotate dehydrogenase (DHODH) and Acetyl-CoA
acetyltransferase (ACAT1) have already been explored as targets
in drug development efforts42,43, and 15 genes were newly
identified. Among these, eight (LSS, NAMPT, FDPS, SQLE, EPHX2,
CAT, CS, SOD2) have been found to inhibit CD4+ T-cell
proliferation upon deletion (Table 2; see more details in
Supplementary Table 2). The product of the reaction catalyzed
by 4-Aminobutyrate Aminotransferase (ABAT) is linked to RA.
Dysregulation of other genes, such as pyruvate dehydrogenase E1
(PDHB), Farnesyl-diphosphate farnesyltransferase 1 (FDFT1), Oxo-
glutarate Dehydrogenase (OGDH), alpha-galactosidase (GAA), has
not been previously reported to impact CD4+ T-cell proliferation.
Furthermore, we predicted 27 possible drug targets for MS. Of
these, glutathione reductase (GSR) and dihydrofolate reductase
(DHFR) were already explored as targets using the experimental
autoimmune encephalomyelitis (EAE) model44,45 and 25 genes
were newly identified. Among these, 12 (CAT, IDH2, HMGCR, PKM,
ABAT, LSS, FASN, PPAT, PNP, CS, CAD, SQLE) have been previously
reported inhibiting CD4+ T-cell proliferation upon deletion. Genes
that were not previously reported to affect CD4+ T cells upon
deletion include Carnitine O-palmitoyltransferase 2 (CPT2), MP
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Dihydropyrimidine dehydrogenase (DPYD), and Farnesyl-
diphosphate farnesyltransferase (FDFT1).
Finally, we identified 24 possible drug targets for PBC. None of
them was previously explored as a drug target in PBC. The
deletion of seven of these potential gene targets (NAMPT, EPHX2,
FASN, ADA, SLC2A3, TXNRD1, ACLY) has been reported to affect
CD4+ T cells in the literature. Genes that have not yet been
reported to affect CD4+ T cells upon deletion include Long-chain-
fatty-acid–CoA ligase 3 (ACSL3), Adenosine kinase (ADK), and S-
adenosylmethionine decarboxylase proenzyme (AMD1).
43 of the 68 predicted drug targets were found for only one
disease. Six drug targets (LSS, ABAT, SQLE, FDFT1, CAT, CS) were
common to RA and MS; five drug targets (NAMPT, EPHX2, COMT,
HIBCH, GAA) were common to RA and PBC; and two drug targets
(ADH5, FASN) were common to MS and PBC. We show the drugs
and compounds available for these targets in Table 3. Out of the
55 unique drug targets identified across three diseases, 38 were
robust across different cutoffs (Supplementary Methods 9). A few
examples of drug targets from purine metabolism, fatty acid
synthesis, and the TCA cycle are shown in Fig. 6.
Experimental validation
Next, we experimentally validated our predictions by targeting
genes that have not been reported in the literature to suppress
CD4+ T-cell proliferation. We selected ten FDA-approved drugs
based on their association with reactions belonging to pathways
we were interested in, while ensuring they would cover at least
one target from each disease. Four of the tested drugs indeed
resulted in decreased CD4+ T-cell proliferation. Genes targeted by
these drugs include COMT (RA, PBC), CPT2 (MS), DPYD (MS), and
ACSL3 (PBC). COMT is associated with five different reactions of
the tyrosine metabolism (Fig. 6f). The genes CPT2 and ACSL3 both
catalyze the production of long-chain Acyl-CoA in fatty acid
biosynthesis from different substrates (Fig. 6c). DPYD catalyzes the
production of uracil and thymine from dihydrouracil and
dihydrothymine in pyrimidine metabolism. We subjected human
CD4+ T cells stimulated with TCR signaling and IL-2 to different
doses of drugs for 48 h and 72 h. Their proliferation was assessed
by the MTT colorimetric cell proliferation assay (Fig. 7). A reduction
of CD4+ T-cell proliferation was observed for every chosen drug.
Entacapone, targeting the COMT gene, showed significant activity
at 48 h and 72 h at 100 μM and 1000 μM (Fig. 7a). EPA, targeting
ACSL3, decreased proliferation at the highest dose (1000 μM) at
72 h, while the other concentrations did not significantly affect
proliferation (Fig. 7b). Perhexiline, targeting CPT2, also reduced
proliferation at 72 h at 100 μM and 1000 μM (Fig. 7c). Fluorouracil,
targeting DPYD, is the only drug that showed an effective impact
on CD4+ T-cell proliferation at a lower dose (1 μM) at 72 h (Fig. 7d).
Interestingly, Entacapone, Perhexiline exhibit a significant
enhancement of proliferation at a low dose (1 μM), indicating
that these drugs can present a biphasic effect in T-cell
proliferation. Our experimental validations thus indicate that the
perturbation of the activity of our predicted targets can impact
CD4+ T-cell proliferation in a time and dose-dependent manner,
as we have recently envisioned46.
Six drugs showed no or opposite effect on the T-cell
proliferation, including DFMO, Pemetrexed, N6022, Ethyl-pyruvate,
Pyrazinamide, and Quercetin. As an example, Fig. 7e shows that
DFMO, targeting ODC1, does not impact T-cell proliferation with
the indicating dose. The data for the other five drugs are shown in
Supplementary Fig. 15.
Taken together, our analysis has identified 68 possible drug
targets of relevance to metabolic regulation of autoimmune
diseases. We discuss the implications of our results in more
detail below.
DISCUSSION
Our predicted drug targets were classified into two categories:
validated and potential. We considered a target to be validated if
previously explored as such in the context of RA, MS, and/or PBC.
Potential targets, those not previously reported as such for the
three diseases we focused on here, were further classified into
three subcategories: target genes that are supported by published
Fig. 4 Model predictions are consistent with the literature. a Dependency of growth rate to varying rate of glucose uptake. b Production of
lactate with increased flux through pyruvate dehydrogenase. c The dependency of growth rate (in all models) on glutamine when glucose
was available (>5 mmol/g DW/hr). d The dependency of growth on glutamine when glucose was removed from the environment. Dots in a, c,
and d are average flux and error bars are standard deviation (n= 5). We varied the uptake rate of glucose or glutamine five times (n= 5) to
obtain the average and standard deviation at each dot. For example, in a, the growth rate at 3.0 mmol/g DW/hr glucose uptake is the average
of growth rates obtained under 3.2, 3.1, 3.0, 2.9, 2.8 (mmol/g DW/hr) of glucose uptake.
B.L. Puniya et al.
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experimental data, predicted target genes for which no data is
currently available, and predicted drug targets for which we
provide experimental validation. We will discuss select examples
of targets in each of these categories to illustrate ways in which
our model and analysis can be used to advance future drug
repurposing as well as drug discovery efforts.
Our predictions include three genes (DHODH, ACAT1, and DHFR)
that code for proteins targeted by approved drugs currently used
Fig. 5 Identification of potential drug targets for RA, MS, and PBC. a Distribution of metabolic drug target genes, and inhibitory drugs or
compounds in each model. b Number of metabolic genes in the models mapped with inhibitory drugs (blue bars) and number of genes
among drugs mapped genes that can block at least one reaction upon inhibition (red bars). c Comparison of metabolic drug targets that
affect reactions upon deletion in CD4+ T-cell models. d Number of all differentially expressed genes (DEGs) and metabolic DEGs in three
diseases rheumatoid arthritis (RA), multiple sclerosis (MS), and primary biliary cholangitis (PBC) (Padj < 0.05). The DEGs were analyzed using
three transcriptomics datasets (one dataset per disease). The data were obtained from peripheral CD4+ T cells of groups of patients and
healthy individuals. e Schematic representation of the integration of disease-associated differentially expressed genes and affected reaction
on each drug target gene perturbation. For each drug target deletion, we investigated how many of fluxes regulated by upregulated genes
are decreased and fluxes regulated by downregulated genes are increased. We used these numbers to calculate PES (perturbation effect score,
see Materials and methods).
B.L. Puniya et al.
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Table 2. Identified CD4+ T-cell drug targets for autoimmune diseases.
Disease Gene Experimental evidence relevant to CD4+ T cells and autoimmune
diseases
RA Lanosterol synthase (LSS) Inhibition of lanosterol synthase (LSS) might decrease the endogenous
cholesterol that may lead to impact cell division97.
4-aminobutyrate aminotransferase (ABAT) GABA downregulates inflammatory response in a mouse model of RA42;
inhibition of ABAT might increase GABA16.
Nicotinamide phosphoribosyltransferase (NAMPT) Nampt inhibition reduces demyelination and disability in EAE56), lack of
NAMPT expression affect T-cell development98.
Farnesyl pyrophosphate synthase (FDPS) Inhibition of FDPS inhibits T-cell cytokine production99.
Squalene monooxygenase (SQLE) Increased membrane cholesterol in T cells leads to an inflammatory
response100.
Farnesyl-diphosphate farnesyltransferase (FDFT1) No support
Bifunctional epoxide hydrolase 2 (EPHX2) Inhibition of EPHX2 pre-clinically evaluated as a drug target for IBD58.
2-oxoglutarate dehydrogenase (OGDH) No support
Catalase (CAT) Protect T cells against oxidative stress101.
Citrate synthase (CS) Inhibition of citrate synthase leads to a reduction in citrate, leading to
reduced proliferation102.
Pyruvate dehydrogenase E1 component subunit beta (PDHB) No inhibition of CD4+ T-cell proliferation under treatment with drug
ethyl-pyruvate (This study)
Catechol O-methyltransferase (COMT) Reduced CD4+ T-cell proliferation when inhibited using drug
entacapone (This study)
3-hydroxyisobutyryl-CoA hydrolase (HIBCH) No inhibition of CD4+ T-cell proliferation under treatment with drug
quercetin (This study)
Superoxide dismutase [Mn], mitochondrial (SOD2) Loss of SOD2 increased superoxide, and defective T-cell development62.
Dihydroorotate dehydrogenase (DHODH) Explored as a potential drug target for RA43 and MS103.
Alpha-glucosidase (GAA) No support
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1) Target of sulfasalazine that is anti-inflammatory indicated for the
treatment of ulcerative colitis and rheumatoid arthritis50.
MS Carnitine O-palmitoyltransferase 2 (CPT2) Reduced CD4+ T-cell proliferation when inhibited using drug perhexiline
(This study)
Catalase (CAT) Protect T cells against oxidative stress101.
ATP synthase subunit alpha (ATP5F1A) No inhibition of CD4+ T-cell proliferation under treatment with drug
quercetin (This study)
ATP synthase subunit beta (ATP5F1B) No inhibition of CD4+ T-cell proliferation under treatment with drug
quercetin (This study)
ATP synthase F1 subunit gamma (ATP5F1C) No inhibition of CD4+ T-cell proliferation under treatment with drug
quercetin (This study)
Ornithine decarboxylase (ODC1) No inhibition of CD4+ T-cell proliferation under treatment with drug
DFMO (This study)
MP cyclohydrolase (ATIC) No inhibition of CD4+ T-cell proliferation under treatment with drug
pemetrexed(This study)
ATP synthase subunit delta (ATP5F1D) No support
ATP synthase F(0) complex subunit B1 (ATP5PB) No support
Alcohol dehydrogenase class-3 (ADH5) No inhibition of CD4+ T-cell proliferation under treatment with
compound N6022 (This study)
Dihydropyrimidine dehydrogenase (DPYD) Reduced CD4+ T-cell proliferation when inhibited using drug perhexiline
(This study)
Isocitrate dehydrogenase (IDH2) Knockdown of IDHl or IDH2 reduces IL-17 producing cells (Patent
WO2017123808A1)104.
Glutathione reductase (GSR) Inhibition of GSH de novo synthesis reduces the pathological
progression of EAE44.
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) Potential target for autoimmune diseases105.
Farnesyl-diphosphate farnesyltransferase (FDFT1) No support
Dihydrofolate reductase (DHFR) Low dose methotrexate (inhibitor of DHFR) found effective for MS, RA,
and Crohn’s disease45.
Pyruvate kinase (PKM) Potential target to regulate inflammation59.
Phosphoribosylglycinamide formyltransferase (GART) No inhibition of CD4+ T-cell proliferation under treatment with drug
pemetrexed (This study)
4-aminobutyrate aminotransferase (ABAT) GABA downregulates inflammatory response in a mouse model of RA42;
inhibition of ABAT might increase GABA16.
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to treat autoimmune diseases42–45,47. A strong example of an
already validated drug target predicted by our models is
dihydroorotate dehydrogenase (DHODH), a key enzyme in the
de novo pyrimidine synthesis pathway, and a target of
leflunomide, an approved drug for rheumatoid arthritis43,48. DHFR
(dihydrofolate reductase) is a well-established oncology drug
target, and also an immunosuppressant and anti-inflammatory
target49. Low doses of an FDA-approved DHFR inhibitor metho-
trexate have been found effective as a treatment for MS, RA, and
Crohn’s disease45. Mitochondrial acetyl-CoA acetyltransferase
(ACAT1) is a target for FDA approved anti-inflammatory drug
sulfasalazine in inflammatory bowel syndrome. Furthermore, this
drug is indicated for treatment for rheumatoid arthritis and
ulcerative colitis50. Taken together, our models successfully
replicated current clinical practice, further strengthening the value
of our approach.
Interestingly, a major subcategory of gene targets we identified
code for proteins that have not previously been explored for the
treatment of RA, MS, and PBC. We can now use these insights to
formulate preclinical and clinical hypotheses. For example, ABAT,
which encodes the GABA-transaminase enzyme that breaks down
γ-aminobutyric acid (GABA; a neurotransmitter), was identified in
our analysis as a potential target. While ABAT has not been
previously identified as a drug target for RA, we can hypothesize
that its inhibition may increase free GABA levels which would, in
turn, inhibit CD4+ T-cell activation. The relationship between
GABA levels and suppressions of CD4+ T-cell activation has been
previously reported, further suggesting a link between neuro-
transmission and immune response51–53. There are currently two
Table 2 continued
Disease Gene Experimental evidence relevant to CD4+ T cells and autoimmune
diseases
Lanosterol synthase (LSS) Inhibition of lanosterol synthase (LSS) might decrease the endogenous
cholesterol, leading to impact cell division97.
Fatty acid synthase (FASN) Fatty acid synthase linked to the pathogenicity of Th17 cells106.
Phosphoribosyl pyrophosphate amidotransferase (PPAT) Knockdown of CAD and PPAT promotes regulatory CD4+ T cells107.
Purine nucleoside phosphorylase (PNP) inhibition leads to T-cell suppression108.
Citrate synthase (CS) Increased citrate in MS patients109.
ADP/ATP translocase 3 (SLC25A6) No support
Carbamoyl-phosphate synthetase 2 (CAD) Knockdown of CAD and PPAT promotes regulatory CD4+ T cells107.
Squalene monooxygenase (SQLE) Increased membrane cholesterol in T cells leads to an inflammatory
response100.
PBC Nicotinamide phosphoribosyltransferase (NAMPT) Nampt inhibition reduces demyelination and disability in EAE56, lack of
NAMPT expression affect T-cell development98.
Inosine triphosphate pyrophosphatase (ITPA) No support
Adenosine kinase (ADK) No support
Long-chain-fatty-acid–CoA ligase 3 (ACSL3) Reduced CD4+ T-cell proliferation when inhibited using drug EPA
(This study)
Thymidine phosphorylase (TYMP) No support
S-adenosylmethionine decarboxylase proenzyme (AMD1) No support
Adenine phosphoribosyltransferase (APRT) No support
Alcohol dehydrogenase class-3 (ADH5) No support
Catechol O-methyltransferase (COMT) Reduced CD4+ T-cell proliferation when inhibited using drug
entacapone (This study)
Bifunctional epoxide hydrolase 2 (EPHX2) Inhibition of EPHX2 pre-clinically evaluated as drug target for IBD58.
3-hydroxyisobutyryl-CoA hydrolase (HIBCH) No inhibition of CD4+ T-cell proliferation under treatment with drug
quercetin (This study)
Fatty acid synthase (FASN) Fatty acid synthase linked to the pathogenicity of Th17 cells106.




Adenosine deaminase (ADA) ADA is a potential target for the treatment of inflammatory disorders110.
Lactoylglutathione lyase (GLO1) No support
Glucose-6-phosphate 1-dehydrogenase (G6PD) No support
Hypoxanthine-guanine phosphoribosyltransferase (HPRT1) No support
Alpha-glucosidase (GAA) No support
Solute carrier family 2, facilitated glucose transporter member 3
(SLC2A3)
Glut3 expressed in differentiated cells and resting equals to glut137.
Multidrug resistance-associated protein 1 (ABCC1) No support
Thioredoxin reductase 1 (TXNRD1) Essential for DNA synthesis during T-cell metabolic reprogramming and
proliferation111.
Superoxide dismutase (SOD1) No support
ATP-citrate synthase (ACLY) Inactivation of ACLY reduces IL-2-promoted CD4+ T-cell growth112.
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Table 3. Drugs and compounds for identified drug targets.
Gene description Drugs/compounda Status of drugs/
compoundsa
Lanosterol synthase (LSS) R0-48-8071 Preclinical
4-aminobutyrate aminotransferase (ABAT) Vigabatrin, phenelzine, valproic acid launched
Nicotinamide phosphoribosyltransferase (NAMPT) FK866 Phase 2
Farnesyl pyrophosphate synthase (FDPS) Pamidronic acid, Zoledronic acid, Alendronic acid, Ibandronate,
Risedronic acid
Launched
Squalene monooxygenase (SQLE) Ellagic-acid Phase 2
Farnesyl-diphosphate farnesyltransferase (FDFT1) TAK-475 Investigational
Bifunctional epoxide hydrolase 2 (EPHX2) GSK2256294A Phase 1
2-oxoglutarate dehydrogenase (OGDH) Valproic acid Launched
Catalase (CAT) Fomepizole Launched
Citrate synthase (CS) Oxaloacetate Phase 2/phase 3
Pyruvate dehydrogenase E1 component subunit
beta (PDHB)
2-oxopropanoate Preclinical
Catechol O-methyltransferase (COMT) Entacapone, Nitecapone, Opicapone Launched, Phase 2,
phase 3
3-hydroxyisobutyryl-CoA hydrolase (HIBCH) Quercetin Launched
Superoxide dismutase [Mn], mitochondrial (SOD2) Tetraethylenepentamine Phase 2/ Phase 3
Dihydroorotate dehydrogenase (DHODH) Atovaquone, Leflunomide, Teriflunomide, Brequinar Launched
Alpha-glucosidase (GAA) Miglitol, Acarbose Launched
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1) Sulfasalazine Launched
Carnitine O-palmitoyltransferase 2 (CPT2) Perhexiline Launched
ATP synthase subunit alpha (ATP5F1A) Quercetin Launched,
ATP synthase subunit beta (ATP5F1B) Quercetin Launched
ATP synthase F1 subunit gamma (ATP5F1C) Quercetin Launched
Ornithine decarboxylase (ODC1) MC-1, Putrescine, DFMO Phase 3, Phase 2,
launched
MP cyclohydrolase (ATIC) Pemetrexed Launched
ATP synthase subunit delta (ATP5F1D) Sevoflurane, Enflurane, Methoxyflurane Launched
ATP synthase F(0) complex subunit B1 (ATP5PB) BTB06584 Preclinical
Alcohol dehydrogenase class-3 (ADH5) N6022 Phase 1/Phase 2
Dihydropyrimidine dehydrogenase (DPYD) 5-fluorouracil, Gimeraci Launched
Isocitrate dehydrogenase (IDH2) AGI-6780 Preclinical
Glutathione reductase (GSR) Carmustine Launched
3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGCR)
Atorvastatin, Fluvastatin, Lovastatin, Meglutol, Pitavastatin,
Pravastatin, Rosuvastatin, Simvastatin, Nadide
Launched
Dihydrofolate reductase (DHFR) Aminopterin, Chlorproguanil, Methotrexate, Pralatrexate,
Proguanil, Pyrimethamine, Sulfameter, Trimethoprim,
Pemetrexed
Launched
Pyruvate kinase (PKM) TEPP-46, 2-oxopropanoate Preclinical
Phosphoribosylglycinamide formyltransferase (GART) Pemetrexed Launched
Fatty acid synthase (FASN) Pyrazinamide, Cerulenin Launched
Phosphoribosyl pyrophosphate amidotransferase (PPAT) Azathioprine, Mercaptopurine Launched
Purine nucleoside phosphorylase (PNP) Acyclovir, Didanosine Launched
ADP/ATP translocase 3 (SLC25A6) Clodronic-acid Launched
Carbamoyl-phosphate synthetase 2 (CAD) Sparfosate Phase 3
Inosine triphosphate pyrophosphatase (ITPA) Citric-acid Preclinical
Adenosine kinase (ADK) ABT-702 Preclinical
Long-chain-fatty-acid–CoA ligase 3 (ACSL3) Eicosapentaenoic acid Launched
Thymidine phosphorylase (TYMP) Tipiracil Launched
S-adenosylmethionine decarboxylase proenzyme (AMD1) Ademetionine, Putrescine Launched, Phase 2
Adenine phosphoribosyltransferase (APRT) Citric acid Preclinical
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FDA-approved drugs, vigabatrin, and phenelzine, that target
ABAT. Although we do not expect that either one of these agents
can be repurposed to treat autoimmune disease given that they
are an anti-seizure medicine and an antidepressant, respectively,
we propose that further analysis of relationships between
neurotransmission and immune response offers an interesting
targeting opportunity42. Another example is glutathione reductase
(GSR), an enzyme that reduces oxidized glutathione disulfide to
cellular antioxidant GSH54. It has been shown that inhibition of the
de novo GSH synthesis can reduce the pathological progression of
experimental autoimmune encephalomyelitis (EAE)44. Here, car-
mustine, a chemotherapy drug, is an FDA-approved drug that
targets GSR, offering a viable starting point for future pre-clinical
testing (Table 3). Additional high confidence predictions and
target candidates are a group of genes that have been
experimentally shown to repress CD4+ T cells upon inhibition.
This list includes nicotinamide phosphoribosyltransferase
(NAMPT), which we now predict is a drug target for RA. This
enzyme is involved in NAD+ synthesis55 and was previously
explored as a drug target in EAE for MS56, melanoma, T-cell
lymphoma, and leukemia57. Given that two NAMPT inhibitors,
GMX1778 and FK-866, are in phase II clinical trials (Table 3), this
enzyme represents a target where pre-clinical testing and follow-
up may lead to drug repurposing opportunities. Another example
worth highlighting is epoxide hydrolase 2 (EPHX2), which converts
toxic epoxides to non-toxic dihydrodiols54,55. Its inhibition was
reported to decrease the production of proinflammatory cytokines
in preclinical evaluation in inflammatory bowel syndrome58. For
EPHX2, an inhibitor GSK2256294A is in phase I clinical trial,
indicating that developing drugs for this target may be possible.
Moreover, our model implicated enzymes such as pyruvate kinase
(PKM), which impacts glycolysis, HMG-CoA reductase (HMGCR),
which regulates cholesterol biosynthesis, and adenosine deami-
nase (ADA), which converts harmful deoxyadenosine to not
harmful deoxyinosine. Each of these enzymes has been experi-
mentally linked to T-cell proliferation and development59–61, and
all three targets have been the subject of previous drug
development campaigns (Table 3). ATP Citrate Lyase (ACLY),
Catalase (CAT), Farnesyl diphosphate synthase (FDPS), Lanosterol
synthase (LSS), Squalene epoxidase (SQLE), and Superoxide
dismutase 2 (SOD2) also represent targets we identified. SQLE is
involved in cholesterol biosynthesis, and in general agreement
with recent reports that inhibiting cholesterol pathways can
suppress T-cell proliferation60. The loss of SOD2 can increase
superoxides and defective T-cell development62. For all these
targets, either preclinical, clinical, or approved inhibitors are
available, which we consider encouraging for further study and
drug repurposing (see Table 3 for details).
Other predicted genes are part of the TCA cycle (Citrate
synthase (CS), Isocitrate dehydrogenase 2 (IDH2)), ribonucleotide
biosynthetic processes (Phosphoribosyl pyrophosphate amido-
transferase (PPAT), Carbamoyl-phosphate synthetase 2, Aspartate
transcarbamylase, and Dihydroorotase (CAD)), and lipid biosynth-
esis (Fatty acid synthase (FASN)) that are also important for T cell
development. As with the examples above, many of these
potential candidate targets have inhibitors that are in different
stages of preclinical and clinical development, and some (like
PPAT and FASN inhibitors) have been FDA approved (Table 3).
In addition to gene targets with robust or partial existing
experimental evidence, we identified 31 potential gene targets for
which no evidence currently exists. These genes are involved in
glycolysis, TCA cycle, OXPHOS, and the metabolism of fatty acid,
pyruvate, purine, pyrimidine, arginine, proline, and tyrosine, which
are all critical for T-cell activation and proliferation39,63. We
performed in vitro experiments to investigate predicted targets
without existing published evidence and we tested ten FDA-
approved drugs. In four cases of drug targets (COMT, ACSL3, CPT2,
and DPYD), the drugs (entacapone, EPA, perhexiline, and
fluorouracil, respectively) inhibited the proliferation of CD4+
T cells in a dose and time-dependent manner. Some drugs
displayed a “biphasic effect” where it encouraged proliferation at a
low dose while inhibiting T-cell proliferation at a higher dose. This
dose–response effect, called hormesis, is usually an adaptive
survival response to toxic agents or stressful environments.
Hormetic effects are, in general, produced by highly conserved
evolutionary systems and characterized by the coordinated
activation of molecular signals triggering coherent metabolic
responses to maintain cell homeostasis64. Indeed, it is well
established that the ability of T cells to modulate their metabolism
upon environmental changes is key to preserve their survival and
fulfill their functions65. In the case of ODC1, we did not observe
any impact on CD4+ T-cell proliferation under any tested
concentration of DFMO at both 48 and 72 h. It is difficult to
explain this lack of effect without further experimental investiga-
tions. It might be that ODC1 is in large excess in our cell cultures,
or that the amount of active enzyme is tightly regulated.
Collectively, our models and approach led to the identification
of potential high-value targets for RA, MS, and PBC treatment, and
proposed several drugs in current clinical use for drug
repurposing.
Data integration enabled us to build, refine, and validate high-
quality cell-type-specific models. While many of the major
pathways important for CD4+ T-cell activation and proliferation
are commonly active across different CD4+ T-cell subtypes we
tested, the models differ with respect to how these pathways are
used for growth. For example, higher activity of the fatty acid
Table 3 continued
Gene description Drugs/compounda Status of drugs/
compoundsa
Adenosine deaminase (ADA) Cladribine, Pentostatin, Dipyridamole, Fludarabine Launched
Lactoylglutathione lyase (GLO1) Indomethacin Launched
Glucose-6-phosphate 1-dehydrogenase (G6PD) RRx-001 Phase 2
Hypoxanthine-guanine phosphoribosyltransferase (HPRT1) Azathioprine, Mercaptopurine Launched
Solute carrier family 2, facilitated glucose transporter
member 3 (SLC2A3)
2-deoxyglucose Phase 2
Multidrug resistance-associated protein 1 (ABCC1) Reversan, Ko143 Preclinical
Thioredoxin reductase 1 (TXNRD1) Fotemustine Launched
Superoxide dismutase (SOD1) Tetraethylenepentamine Phase 2/Phase 3
ATP-citrate synthase (ACLY) ETC-1002 Phase 3
aData obtained from repurposing tool84 of cMap database and DrugBank50.
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oxidation pathway is more important in naïve but not in effector
CD4+ T cells that have elevated glycolysis63 and fatty acid
synthesis pathways. A substantial number of essential genes
identified from these models overlapped with gene essentiality
data obtained from different cell lines41. When compared to gene
essentiality from independent cell line data, the effector cell
models performed slightly better than the naïve model. One
possible reason for this difference might be the difference in
nutrient preferences between naive and effector T cells. We are
conscious that assessing model performances based on compar-
ison with essential genes defined on different cell lines is not ideal.
Properly assessing their accuracy would require CD4+ T-cell-
specific essentiality data. Integration of disease-associated DEGs
with flux profiles under gene knock-out helped us to select
disease-specific drug targets. While computational models of
signal transduction in CD4+ T cells66,67 are available, metabolic
Fig. 6 Examples of identified drug targets mapped on the metabolic pathways. Relevant sub-networks of pathways where drug targets
were mapped are shown for a pyruvate metabolism, b TCA cycle, c fatty acid biosynthesis, d steroid biosynthesis, e purine metabolism, and
f tyrosine metabolism. The mapped drug targets (bold font) and diseases (in brackets) are shown in blue colored text.
B.L. Puniya et al.
12
npj Systems Biology and Applications (2021)     4 Published in partnership with the Systems Biology Institute
models of effector and regulatory CD4+ T cells have not been
developed (except for naïve CD4+ T cells34). Similar metabolic
models were previously used to predict drug targets against
pathogens18 and complex diseases such as cancers68.
While our approach can be generalized for human diseases and
used with any -omics dataset, the unavailability of reliable data
contributes to some limitations. Because of heterogeneity with
respect to time after stimulation with cytokines in the available
datasets, constructed models represent inclusive metabolic
phenotypes during activation and proliferation for each CD4+ T-
cell subtype. Thus, time-specific data would be required to study
metabolic phenotype at a specific time point in CD4+ T-cell
development. Furthermore, by integrating gene expression and
proteomics data, we improved the identification of expressed
genes compared with the sole use of gene expression or
proteomics datasets. This approach presents certain limitations
because of post-transcriptional and post-translational modifica-
tions. Integrating more functional data such as enzyme activities
and measured metabolic fluxes could further improve the
selection of active reactions within the context of specific models.
In addition, the biomass objective function used in our study is not
specific to CD4+ T cells. We used a biomass objective function
generated for human alveolar macrophages. Differences in growth
conditions and the respective sizes of macrophages and CD4+
T cells might impact the ratios of precursors used for biomass
objective functions. Since the precursors for biomass production
would be the same across different cell types, in the absence of
comprehensive data on precursor ratios from a specific cell type,
the objective function of similar cells is useful for obtaining flux
distribution. A specific objective function that considers varying
utilization of precursor metabolites (such as glycolysis intermedi-
ates) by different CD4+ T cells for biomass production might
Fig. 7 Analysis of CD4+ T-cell proliferation response upon drug treatment by MTT assay. CD4+ T cells were exposed to various
concentrations of drugs (1, 10, 100, and 1000 μM) for 48 h (white bars) and 72 h (orange bars). Drugs’ names (Entacapone, EPA, Perhexiline,
Fluorouracil, and DFMO) were indicated on the top of each graph bar with their corresponding targeted gene in parentheses. Cell
proliferation is expressed as fold change ± SEM relative to untreated control cells and is representative of four independent experiments.
Statistic significance was only shown for effective concentration and was evaluated using a paired t-test, one-tailed (*p < 0.05, **p < 0.005).
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further improve the models. However, we have shown that
changing objective functions (from the Recon3D to macrophage
model) had no significant impact on the constructed models (see
Materials and methods for details). Similarly, reliable disease-
specific data were unavailable for specific CD4+ T-cell subtypes,
therefore, building subtype-specific cell metabolic models under
disease conditions was not possible. We mitigated this limitation
by integrating disease-specific DEGs from sorted CD4+ T cells with
models, which resulted in metabolic fluxes relevant to diseases. In
the future, with the availability of more disease and cell-type-
specific data, our integrative approach may further improve these
results. In particular, we hope to include other cell-types such as T
follicular helper (Tfh),T helper 9 (Th9), and T helper 22 (Th22) cells,
which also play a role in the development of autoimmune
diseases.
Overall, our integrative systems modeling approach has
provided a new perspective for the treatment of RA, MS, and
PBC. Moreover, the newly constructed models may serve as tools
to explore the metabolism of CD4+ T cells. Additionally, our
approach is generalizable to other disease areas for which reliable
disease-specific data are available, making it a potentially
important computational platform for both drug target identifica-
tion and prioritizing targets for drug repurposing efforts.
MATERIALS AND METHODS
High throughput data acquisition and integration
We collected transcriptomics data from the GEO69 database and
proteomics data31. A total of 121 transcriptomics22–30 and 20 proteomics31
samples relevant to the CD4+ T cells were selected (Supplementary Data
1). Transcriptomics data analysis was performed using the affy70 and
limma71 R packages. Because we aimed to characterize gene activities
instead of gene expression levels, the processed transcriptomics data were
discretized (active= 1; inactive= 0) and samples for each cell type were
combined. Genes expressed in more than 50% of the samples in which the
probe was present were considered as active (see Supplementary Methods
2). Similarly, proteins expressed in more than 50% of samples in the
proteomics dataset were considered as active. In the proteomics datasets,
protein IDs were mapped to gene IDs.
Next, we integrated activities from transcriptomics and proteomics
datasets. First, biological entities that overlapped in both types of data
were selected as high-confidence. Second, we found that some genes
were expressed in the majority of transcriptomics datasets, but expressed
in less than 50% samples of proteomics data. Similarly, some proteins were
identified within groups of highly abundant proteins in multiple samples in
proteomics datasets but expressed in less than 50% samples of
transcriptomics datasets. Such non-overlapping genes were selected as
moderate-confidence based on consensus in single types of -omics data
(Supplementary Methods 2.1.1). Third, moderate-confidence genes exclu-
sively present in the transcriptomics data were added to the overlapping
genes if expressed in at least 90% of samples. Fourth, moderate-
confidence genes exclusively present in the proteomics dataset were
added if their abundance was ranked in the top 25% (fourth quartile)
(Supplementary Methods 2; Supplementary Data 10). We used these
cutoffs to decrease the false negatives while not selecting false positives
by removing genes and proteins that are not expressed in any sample
either in transcriptomics or proteomics data.
Cell type-specific genome-scale metabolic model
reconstruction
We used the GIMME72 method (in COBRA toolbox) to construct the
metabolic models of different CD4+ T cells (naïve, Th1, Th2, Th17). The
inputs for GIMME were the generic human Recon3D35 (as a template) and
gene expressions based on integrated multi-omics data. The template
Recon3D was modified prior to constructing CD4+ T-cell-specific metabolic
models. These modifications included gene–protein-reaction (GPR) asso-
ciations (all genes associated with a reaction written using AND and OR
operators), media conditions, and reaction directionality. In the original
Recon3D, GPRs used transcript IDs. Because our data included gene IDs, we
mapped the transcript IDs to the gene IDs. For naïve and effector cells,
different types of media conditions were selected based on nutrient
preference information obtained from the literature (Supplementary
Methods 2.1.2). In addition, new reactions involved in the biomass
objective function were added, and some reactions were removed as
described below (see also Supplementary Methods 2). The transcriptomics
and proteomics data have information about genes/proteins instead of
transcript variants. To map the data obtained for genes, we updated
transcript IDs provided in Recon3D to Entrez gene IDs. A total of 1892
genes were included in the modified Recon3D model. Furthermore,
because different CD4+ T cells have different nutrient uptake preferences,
we used two types of media conditions (one for each naïve and one for all
effector T cells), shown in Supplementary Methods 2.1.2.4. For all cell
subtypes, in addition to the basal metabolites (freely available, i.e., H2O, O2,
H, O2S, CO2, Pi, H2O2, HCO3, H2CO3, and CO), glucose, glutamine, and other
amino acids were set as open (but tightly constrained) for uptake. The
major difference in media condition was the presence of fatty acids in the
naïve model. Furthermore, during the refinement of the CD4+ T-cell
models, the directionality of some reactions was updated based on the
Recon 2.2.05 model73 and the MetaCyc database (Supplementary Methods
2.1.2.5 and 2.2.3). Because of the lack of CD4+ T-cell-specific data, the
biomass objective function was adopted from the macrophage model iAB-
AMØ-141074 and added to the Recon3D.
For each subtype, we constructed three models based on transcrip-
tomics, proteomics, and integrated (transcriptomics and proteomics data)
datasets. A comparison of these models is provided in Supplementary Fig.
16 and details can be found in Supplementary Methods 2. The models
constructed with integrated data were selected for further analysis.
Additionally, to investigate the effect of biomass objective function on
constructed models, we built two models using biomass objective
functions from (1) Recon3D and (2) iAB-AMØ-1410 models. The reactions
in output models generated based on each biomass function were
compared. The models based on the two objective functions were not
significantly different (Supplementary Fig. 17) with respect to the numbers
of reactions. Biomass objective function from iAB-AMØ-1410 consists of
few extra precursors that predicted better fluxes through fatty acid
pathways. The literature has shown that effector CD4+ T cells synthesize
fatty acids, whereas naïve CD4+ T cells exhibit fatty acid oxidation. We
compared the fluxes of models created with objective functions from
Recon3D and iAB-AMØ-1410. The models created with biomass objective
function adopted from iAB-AMØ-1410 had more reactions carrying non-
zero flux in the fatty acid pathways (than the models created with Recon3D
biomass objective function). Therefore, models that are constructed based
on biomass reaction adopted from iAB-AMØ-1410 were used in
subsequent analyses. Models were further reduced by removing the
dead-end reactions. Reactions in the models are distributed across
different compartments including extracellular, cytoplasm, mitochondria,
nucleus, Golgi apparatus, lysosome, and endoplasmic reticulum. The
models were investigated to perform basic properties using leak tests,
gene deletion, and further refined in an iterative manner. To examine leaks,
we simulated the models with all the exchange reactions closed and
analyzed all the reactions individually for non-zero flux. If the models were
producing metabolites, the mass imbalance was checked and fixed. We
used a gene deletion analysis to check if the model was able to predict
gene essentiality. Because effector T cells are highly glycolytic, deleting
glucose transporters should result in reduced growth. We used this as a
reference to check that the model was behaving correctly. Furthermore,
we investigated if inhibiting acetyl-CoA carboxylase (ACC1)—which was
experimentally observed as essential for CD4+ T-cell function—resulted in
altered growth. These analyses helped us identify problematic reactions
that were corrected based on Recon2.2.05—a manually curated model for
mass charge balancing and reaction directionality—and the MetaCyc
database. Refined models were then subjected to 460 metabolic tasks that
were used with the Recon3D model and included in Test4HumanFctExt
function in COBRA (Supplementary Data 11). The constructed models were
simulated using Flux Balance Analysis (FBA) and Flux Variability Analysis
(FVA). The final numbers of metabolites and reactions are presented in
Supplementary Table 1. These models were named as TNM1055 (naïve
model), T1M1133 (Th1 model), T2M1127 (Th2 model), and T17M1250 (Th17
model). The models encoded in json can be found as Supplementary Data
3–6. They have also been submitted to BioModels database75 under
accessions MODEL1909260003, MODEL1909260004, MODEL1909260005,
MODEL1909260006.
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Model validation
Models were validated based on literature knowledge related to active
pathways in proliferating and differentiated CD4+ T cells. CD4+ T-cell-
specific metabolic functions were searched in the literature using
PubMed76. Naïve CD4+ T cells tend to have low energy demands and
mainly rely on fatty acid β-oxidation, oxidation of pyruvate, and glutamine
via the TCA cycle77. On the other hand, the high bioenergetics demand in
effector cells is met by shifting OXPHOS to glycolysis and fatty acid
oxidation to fatty acid synthesis39. Furthermore, similar to cancer cells,
proliferating effector CD4+ T cells convert lactate from pyruvate by lactate
dehydrogenase enzyme39. Thus, we obtained the flux distribution of
metabolic pathways under wild-type conditions using Flux Balance
Analysis (FBA) and searched the non-zero fluxes through the aforemen-
tioned pathways in all the models. Flux maps were created using Escher
web application (https://escher.github.io/#/)78,79. It has also been observed
previously that deficiency in glucose and glutamine impairs CD4+ T-cell
activation and proliferation37,80. We performed this experiment in silico,
whereby we varied the flux through exchange reactions of glucose
(EX_glc_D[e]) and glutamine (EX_gln_L[e]) in the models and analyzed the
effect on growth rate.
Comparison of essential genes predicted by the models and
identified in different cell lines
To predict gene essentiality, we knocked out model genes to predict their
effect on the growth rate. This was performed using singleGeneDeletion in
the COBRA toolbox using the Minimization of Metabolic Adjustment
(MoMA) method81. Because of the unavailability of CD4+ T-cell-specific
data, predicted essential genes were compared with experimentally
identified essential genes in humans from different cell lines. The data
for experimentally tested essential and nonessential genes for human were
obtained from the OGEE database41. In this database, the essentiality data
for humans was compiled using 18 experiments across various cell lines
that include RNAi-based inhibition, CRISPR, and CRISPR-CAS9 systems. To
investigate how many model-predicted essential genes are also essential
in other cell lines, predicted essential genes were compared with
experimentally observed essential and conditionally essential genes
reported in the OGEE database. Essential and conditionally essential genes
were merged together. Additional validations of models using CD4+ T-cell-
specific essential genes can be found in Supplementary Methods 3.
Mapping drug targets
The developed models were used to predict potential drug targets for
autoimmune diseases in which effector subtypes have been found
hyperactive82,83. Therefore, a reasonable drug target should downregulate
effector CD4+ T cells. Among the metabolic genes of selected models, we
first identified targets of existing drugs. The drugs and their annotations
including target genes were imported from The Drug Repurposing Hub84
in the ConnectivityMap (CMap) database85 (see also Supplementary
Methods 4). All withdrawn drugs and their annotations were first removed.
In this list, the gene symbols of target genes of drugs were converted to
Entrez IDs. Next, we searched Entrez IDs from CMap data in the genes of
metabolic models. For each mapped gene in the model, the drugs were
listed.
Metabolic genes differentially expressed in autoimmune
diseases
The lack of reliable data from specific CD4+ T-cell subtypes involved in
autoimmune disease conditions led us to utilize patients’ data (case-
control studies) available for autoimmune diseases that were collected
from peripheral CD4+ T cells. Datasets GSE5664986 (rheumatoid arthritis),
GSE4359187 (multiple sclerosis), and GSE9317088 (primary biliary cholangi-
tis) were obtained from the GEO database (see details in Supplementary
Methods 5). Raw data files were processed using the affy and limma
packages70,71 in Bioconductor/R. The limma package was used to identify
DEGs between patients and healthy controls. For significant differential
expression, selective cutoffs of fold-changes were used with adjusted P-
values < 0.05. For differentially expressed genes, we used a two-fold cutoff.
A cutoff of 1.5-fold was used for datasets where two-fold resulted in a very
low number to zero differentially expressed metabolic genes.
Perturbation of metabolism and perturbation effect score
(PES)
In metabolic models, the knockout of genes that are targets of existing
drugs was performed in the COBRA toolbox using MoMA81 (Supplemen-
tary Methods 6). For each knockout, we investigated the change in fluxes
regulated by DEGs in diseases. The change in fluxes was computed using
flux ratios of perturbed flux/WT flux, and all fluxes that are affected by each
perturbation were calculated. We counted fluxes regulated by upregulated
genes that are decreased or increased after perturbation (UpDec and
UpInc) as well as fluxes regulated by downregulated genes that are
decreased or increased after perturbation (DownDec and DownInc). The
total number of fluxes for each perturbation also include upregulated
genes that were unchanged after perturbation (UpUnc) as well as
downregulated genes that were unchanged after perturbation (DownUnc)
(see also Supplementary Methods 7). For each perturbed gene, a
perturbation effect score (PES) was calculated as:
PES ¼ ðUpDec  UpIncÞðUpDec þ UpInc þ UpUncÞ þ
ðDownInc  DownDecÞ
ðDownInc þ DownDec þ DownUncÞ
(1)
Next, for each disease and model combination, the ranks of PES were
computed. The gene with the highest PES obtained the top rank and the
one with the minimum PES obtained the lowest rank. For each disease, we
prioritized drug targets by utilizing their ranks across all models. The PES
ranks in each model were first transformed into Z-score as:
Z  score ¼ ðx  μÞ
σ
(2)
where x is a PES rank, μ is the mean of PES ranks in a model for one
disease, σ is the standard deviation of PES ranks obtained by a model for
one disease. For each disease type and each gene, Z-scores across four
models were summed up to calculate an aggregated Z-score. Genes were
ranked based on minimum to maximum aggregate Z-scores (Supplemen-
tary Methods 8).
Pathway enrichment analysis
For biological processes enrichment analysis, we used DAVID V6.889, and
STRING database90 together with Gene Ontology biological processes91,
KEGG pathways92, and Reactome pathways93. A cutoff of 5%94,95 False
Discovery Rate (FDR) and P-value < 0.05 were used for significant
enrichment.
The pathway maps used in Fig. 6 were generated with yED graph editor
software. The ChEMBL IDs96 of drug targets can be found in Supplemen-
tary Table 2.
Experimental validation
We used frozen vials of peripheral blood mononuclear (IXCells Biotechnol-
ogies) from healthy donors. CD4+ were purified by negative selection
using magnetic human CD4+ T cells nanobeads (MojoSort, Biolegend)
according to the manufacturer’s protocol. For cell activation, anti-CD3
(clone OKT3, Biolegend) was coated on plates at 4 µg/ml overnight in PBS
at 4 °C. Cells were then cultured in X-Vivo media (Lonza) supplemented
with 2 µg/ml of anti-CD28 (clone CD28.2, Biolegend) and with 10 ng/ml of
recombinant IL-2 (Peprotech) for 7 days. Half of the media was renewed
every 2–3 days by adding fresh media supplemented with 2 µg/ml of anti-
CD28 and 10 ng/ml IL-2.
We purchased alpha-difluoromethylornithine (DFMO) and eicosapentae-
noic Acid (EPA) from Cayman Chemical. DFMO was resuspended in water
at 50mM while EPA was already resuspended in ethanol at 826mM.
Perhexiline, Entacapone, and Fluorouracil were obtained from Tocris and
dissolved in DMSO to make a stock solution at 12mM, 200mM, and
198mM, respectively. For drug treatment, CD4+ T cells were seeded at
50,000 cells in 96 round bottom wells in culture media supplemented with
anti-CD3, anti-CD28, and IL-2. Before incubation with CD4+ T cells, drugs
were diluted in culture media with concentration ranging from 1 µM to
1000 µM and incubated for 48 h or 72 h.
We assessed T-cell proliferation using the TACS MTT proliferation assay
(R&D Systems). Briefly, a tetrazolium salt solution (10 μl) was added to each
well, and the plate was incubated at 37 °C for 4 h. After incubation, 100 μl
of stop solution was added to each well and incubated overnight before
absorbance measurement. Cell proliferation was read at 48 h and 72 h post
drug treatment. The absorbance was measured at 570 nm using the BioTek
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microplate reader instrument (BioSPX). We corrected cell absorbance
readings using cells treated with DMSO or the media controls.
The CD4+ T-cell proliferation upon drug treatment was analyzed
statistically with a paired t-test, one-tailed for four independent experi-
ments. All data are presented as mean plus or minus standard error of the
mean (SEM) and analyzed using GraphPad Prism software. The fold change
of cell proliferation-cultured was calculated using untreated cells as 1.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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